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Premature infants (PI) are neonates born <37 weeks
gestational age, with different PI subgroups being identi-
fied according to gestational age and birth weight.
Prematurity is associated with increased morbidity and
perinatal mortality, since yields increased risk for a
number of pathological features and negative outcomes
related mainly to the extent of all organs and functions’
immaturity. Among these conditions, neonatal and post-
natal infections play a major role. PI feature increased
odds of infections and infections-related morbidity
throughout their first months of life.
Among all preventative, anti-infective strategies, active
vaccination is a key point for PI.
The most common vaccine-preventable diseases in PI
are whooping cough, Haemophilus influenzae type-b
(Hib) meningitis, invasive pneumococcal disease, rota-
virus gastroenteritis, influenza.
International guidelines recommend to deliver active
immunization following the chronological timing
(=counting the weeks of actual birth), and not following
the corrected gestational age (=counting the weeks of
life starting from the expected moment of birth). How-
ever, vaccinations in PI are often performed later than
recommended, or even less than expected, as shown by
recent studies carried out in Italy assessing significantly
decreased rates of active immunization in PI.
This somewhat poor adherence to the international
guidelines is related to concerns about weaker immune
responses in PI, and possible adverse events.
Nonetheless, several studies have shown that vaccines
administered to PIs have excellent safety profiles, fully
comparable to term infants.
Transient, benign episodes of apnea, with or without
associated bradycardia, have been occasionally described
in PI occurring up to 48 hours post-immunization.
Though no significant morbidity nor long-term sequelae
has been associated with these events, it is advisable to
monitor these episodes for 48 hours after the comple-
tion of vaccination.
Vaccines are immunogenic, generally safe and well tol-
erated in all infants including PI. Noteworthy, only vac-
cines specifically authorized for use in premature infants
should be used in PIs. The most immature neonates
(i.e., ELBW infants) should receive their first dose of
vaccine during hospitalization, in order to allow such
risky groups of infants achieving sufficiently protective
immunization before their discharge. This strategy also
allows for adequate monitoring of cardiorespiratory
function, and ultimately improves adhesion to the vacci-
nation programs.
Strategies aiming at promoting education and aware-
ness about vaccination practices and recommendations
in PI should be reinforced. The ultimate aim is to
increase delivery of effective protection against vaccine-
preventable diseases to these vulnerable patients since
their discharge from the NICU.
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